Abstract: Epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) has continued to lend to the precise treatment of EGFR mutations in advanced non-small cell lung cancer for more than ten years, which the efficacy of EGFR-TKI for patients with common EGFR mutations in advanced NSCLC has been demonstrated clearly. However, for uncommon EGFR mutations, the efficacy of EGFR-TKI is still exist many dispates. This article lists the median progression-free and overall survival of the drugs of EGFR-TKI that have entered the clinical stage in EGFR mutation-positive advanced NSCLC currently making comparisons, and add correlation studies on the efficacy of EGFR-TKI for those patients with uncommon EGFR mutation. It is hoped to provide reference for rational application of EGFR-TKI in clinical.